BOCA RATON, Fla., Jan. 6, 2012 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc.announced that it has submitted Paragraph IV (PIV) certifications for seven (7) different Abbreviated New Drug Applications (ANDA) during the 2011 calendar year and intends to submit at least five (5) each year for the next several years. These submissions reflect Breckenridge's aggressive strategy to focus on Paragraph IV opportunities -- both blockbuster and niche products -- as an integral part of its business model. Breckenridge's PIV portfolio includes a mix of first-to-file and late-stage opportunities.
Breckenridge continues to look for new ANDA opportunities from development partners, whereby Breckenridge will submit the applications as PIV's and wholly manage the resulting litigation. Utilizing its in-house legal and regulatory staff, Breckenridge offers a turnkey Paragraph IV-litigation solution while maximizing cost efficiency.
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, and Liquids, and Powders. www.bpirx.com
SOURCE Breckenridge Pharmaceutical, Inc.